Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC42 | P60953 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | RB1 | P06400 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449921 | 0.87 | CDC42 (0.80) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL5456587 | 0.87 | CDC42 (0.70) | CDC42GAACASP6DHODHPRMT5 | |
| SCHEMBL5467904 | 0.84 | CDC42 (0.66) | CDC42GAACASP6DHODHPRMT5 | |
| SCHEMBL4187019 | 0.81 | GAA (0.72) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL5447038 | 0.81 | BRD3 (0.63) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL14361488 | 0.81 | CDC42 (0.61) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL4196072 | 0.81 | CYP2D6 (0.67) | CDC42GAACASP6DHODHPRMT5 | |
| SCHEMBL5461141 | 0.81 | CDC42 (0.76) | CDC42GAACASP6PRMT5CYP2D6 | |
| SCHEMBL5458904 | 0.81 | RB1 (0.64) | CDC42GAACASP6DHODHPRMT5 | |
| SCHEMBL4192405 | 0.80 | RB1 (0.60) | CDC42GAACASP6PRMT5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | CDC42 1241/4885GAA 1417/4885CASP6 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.